Although a common theme across adult onset neurodegenerative diseases, the pathogenic role of aggregated proteins is a continuous topic of debate. For the incurable familial neurodegenerative disorder Huntington's disease (HD), resolving the accumulation of mutant huntingtin (Htt) (neuronal or cytoplasmic) is highly correlated with favorable therapeutic outcomes. Whether targeting aggregate clearance per se is beneficial, however, has remained unclear. We have previously identified a pathway by which aggregated proteins are selectively eliminated by the lysosome-mediated pathway macroautophagy. We found that the protein Alfy is central for the selective turnover of aggregates in cell based systems. During the previous funding period, we used a mouse genetics and cell biology to determine that Alfy is indeed essential turnover of aggregated proteins in adult brain, and diminishing Alfy levels in vivo modifies disease onset. In this renewal application, we will use genetic and molecular based approaches to determine if augmenting Alfy levels promotes the elimination of aggregated nuclear and cytoplasmic proteins, the mechanism by which a genetic variant of Alfy might delay the age of onset of MD, and the molecular mechanism by which Alfy permits aggregate clearance. .

Public Health Relevance

Protein aggregation may be at the root cause of much of the pathology associated with adult onset neurodegenerative disease. This proposal aims to determine if this is the case, by determining if the turnover of aggregates can ameliorate diseases such as Huntington's disease in mice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS077111-06
Application #
9913588
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Miller, Daniel L
Project Start
2012-04-01
Project End
2024-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Neurology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Eenjes, Evelien; Dragich, Joanna M; Kampinga, Harm H et al. (2016) Distinguishing aggregate formation and aggregate clearance using cell-based assays. J Cell Sci 129:1260-70
Dragich, Joanna M; Kuwajima, Takaaki; Hirose-Ikeda, Megumi et al. (2016) Autophagy linked FYVE (Alfy/WDFY3) is required for establishing neuronal connectivity in the mammalian brain. Elife 5:
Yang, X William; Yamamoto, Ai (2014) CLEARance wars: PolyQ strikes back. Nat Neurosci 17:1140-2
Prè, Deborah; Nestor, Michael W; Sproul, Andrew A et al. (2014) A time course analysis of the electrophysiological properties of neurons differentiated from human induced pluripotent stem cells (iPSCs). PLoS One 9:e103418
Nath, Sangeeta; Dancourt, Julia; Shteyn, Vladimir et al. (2014) Lipidation of the LC3/GABARAP family of autophagy proteins relies on a membrane-curvature-sensing domain in Atg3. Nat Cell Biol 16:415-24
Tang, Guomei; Gudsnuk, Kathryn; Kuo, Sheng-Han et al. (2014) Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 83:1131-43
Yamamoto, Ai; Yue, Zhenyu (2014) Autophagy and its normal and pathogenic states in the brain. Annu Rev Neurosci 37:55-78
Shoji-Kawata, Sanae; Sumpter, Rhea; Leveno, Matthew et al. (2013) Identification of a candidate therapeutic autophagy-inducing peptide. Nature 494:201-6
Johnson, Christopher W; Melia, Thomas J; Yamamoto, Ai (2012) Modulating macroautophagy: a neuronal perspective. Future Med Chem 4:1715-31
Mijaljica, Dalibor; Nazarko, Taras Y; Brumell, John H et al. (2012) Receptor protein complexes are in control of autophagy. Autophagy 8:1701-5